Azacitidine

Catalog No.S1782 Synonyms: NSC 102816

Azacitidine  Chemical Structure

Molecular Weight(MW): 244.2

Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Cells were treated with 50 µM AZA and 2 different concentrations of each HDACi for 72 h before cell viability was determined. Data is represented as percent in comparison to vehicle (DMSO) treated cells (set to 100%).

    Epigenetics, 2015, 10(5): 431-45. Azacitidine purchased from Selleck.

    (A) The graph shows percentage of human CD45+ leukemic cells in mouse blood. At time 0, mice were injected with MV4;11 cells. The arrow indicates when drug treatment began. (B) Kaplan-Meier plot shows the percentage of mice surviving following treatment. The p-value for median survival between different treatment groups (by ANOVA) is<0.0001. The mice treated with the combination of azacitidine and panobinostat were disease-free until they were sacrificed 18 months post cell injection.

    Leuk Res, 2017, 58:91-97. Azacitidine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.
Targets
DNA methyltransferase [1]
(Cell-free assay)
In vitro

Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. [1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. [2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Raji  M4Dk[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmwMlEuPTBizszN MmfSNVIuPzJiaB?= MVXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> Ml7iNlYyOzN{NE[=
Jurkat  NIfkZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnUNE4yNTVyIN88US=> M4ntWFEzNTd{IHi= NFzFTJBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NUntXVBQOjZzM{OyOFY>
CA46 MUjGeY5kfGmxbjDBd5NigQ>? MoroNlDDqML3TR?= M1jYO|Q5KGh? M3Xidolv[3KnYYPld:KhWFSSTEJCpI1TVkFiZYjwdoV{e2mxbh?= MV[yOlE{OzJ2Nh?=
Raji  M1nTcGZ2dmO2aX;uJGF{e2G7 NXfncFRiOTYEoNM1US=> MXK0PEBp MWPpcoNz\WG|ZYRCpHBVWExzwrDtVm5CKGW6cILld5Nqd25? NX\XU3YxOjZzM{OyOFY>
Jurkat  NIK5eWhHfW6ldHnvckBCe3OjeR?= NHKzSoo{NjYEoNM1US=> MVO0PEBp MUjpcoNz\WG|ZYRCpHBVWExzwrDtVm5CKGW6cILld5Nqd25? MlLNNlYyOzN{NE[=
MDA-MB-231 MYLGeY5kfGmxbjDBd5NigQ>? M{nKVlEwOi53L{Wg{txO MX20PEBp NHnoU5Jl\WO{ZXHz[ZMhfGinIGDUVG4yOiCneIDy[ZN{cW:wIHH0JJRp\SClb37j[ZJvfHKjdHnvckBw\iB3wrFOwG0hPDkEoHi= MXiyOVgyPzJ{OR?=
MDA-MB-231 M1Ky[WZ2dmO2aX;uJGF{e2G7 MYSxM|IvPS93IN88US=> MWq0PEBp M3PpR4lv[3KnYYPld{B1cGVibHX2[Yx{KG:oIFWtZ4FlcGW{aX6gcXJPSSCjdDD0bIUh[2:wY3XycpRz[XSrb36gc4YhOi53wrFOwG1nd3JiNElCpIg> NH;XVGozPThzN{KyPS=>
MDA-MB-231 NWS0NG1JTnWwY4Tpc44hSXO|YYm= M1Xz[lEwOi53L{Wg{txO MX2yOE81QCCq NF3hbpZqdmS3Y3XzJEB{cWewaX\pZ4FvfCCSQWLQJINt\WG4YXflJIFnfGW{IES4JIg> MknBNlU5OTd{Mkm=
MCF-7 M{XKUWZ2dmO2aX;uJGF{e2G7 NWnQbnlEOS9{LkWvOUDPxE1? Mom3NlQwPDhiaB?= M3L2TYlv[3KnYYPld{BRSVKSIHPs[YF3[WenwrC= NHPVS3MzPThzN{KyPS=>
MDA-MB-231  NVHqdWFqTnWwY4Tpc44hSXO|YYm= MoHsNU8zNjVxNTFOwG0> MnTjNlQwPDhiaB?= MlfLbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJI1qWk6DLUGyOEBifCC2aHWgZ49v[2W{boTyZZRqd25ib3[gOUDPxE1? MkLiNlU5OTd{Mkm=
A498 NX21UpdrTnWwY4Tpc44hSXO|YYm= M3XlSVExKML3TR?= NU\HSmVTPzJiaB?= M3zCcolv\HWlZYOgeIhmKEGGQV3UV|E5KGenbnWg[ZhxemW|c3nvci=> M1K4cVI2PTZ7MEi2
CaKI-2 NV3hR4hGTnWwY4Tpc44hSXO|YYm= MV2xNEDDvU1? M2DuW|czKGh? NWDWRpVQcW6mdXPld{B1cGViQVTBUXRUOThiZ3Xu[UBmgHC{ZYPzbY9v MVmyOVU3QTB6Nh?=
Ketr-3 NYT6N49NTnWwY4Tpc44hSXO|YYm= NYjtd4NPOTBiwsXN NUTCZ455PzJiaB?= Ml7GbY5lfWOnczD0bIUhSUSDTWTTNVgh\2WwZTDlfJBz\XO|aX;u MX:yOVU3QTB6Nh?=
A253 MWDGeY5kfGmxbjDBd5NigQ>? M4PtTFExKML3TR?= M4eyTVAuPCCm M4TPdYlv[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKGyndnXsJI9nKHSqZTDNN3LDqGGodHXyJFI1KGh? MU[yOVQ5PTV|Nh?=
A253 MmHiSpVv[3Srb36gRZN{[Xl? NX;oRph5OTBiwsXN MVe3NkBp MX\pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZidHjlJG0{WiCrbjDic5RpKG2nbXLyZY5mKGGwZDDjfZRwe2:uaXOgdJJmeGG{YYTpc45{ Mlu0NlU1QDV3M{[=
A253 M3G0PWZ2dmO2aX;uJGF{e2G7 M1HNc|ExKML3TR?= NXfCdXNsOC12IHS= NVvNc3dIemWmdXPld{B1cGViNT3t[ZRpgWyleYTvd4lv\SClb370[Y51 NWq1WHV1OjV2OEW1N|Y>
PC3 NXyxPHBJTnWwY4Tpc44hSXO|YYm= NGTQTYUxNjJizszNxsA> M1TVfVQh\A>? MV\pcoNz\WG|ZYOgeIhmKGenbnWg[ZhxemW|c3nvckBw\iCLR1\CVFctKFOIUmCxJIFv\CCVTFO2RVE2KGOxbXLpcoVlKHerdHigS3NMOTJ4 NHzYV3czPTR5N{O0NC=>
MCF7 NVqwXWlZTnWwY4Tpc44hSXO|YYm= NUnNbWV{OC5|IN88UeKh MnrROEBl MmLobY5kemWjc3XzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiSVfGRnA4NCCVRmLQNUBidmRiU1zDOmEyPSClb33ibY5m\CC5aYToJGdUUzF{Nh?= NWCwTlFKOjV2N{ezOFA>
PC3 NYTGXG11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PDelAvOiEQvF5CpC=> MoSzOEBl NXjucHVy\GWlcnXhd4V{KHSqZTDj[YxtKGe{b4f0bEB1dyB{MD6zKUBkd22kaX7l[EB4cXSqIFfTT|EzPg>? NFnMZnozPTR5N{O0NC=>
MCF7 NEXESIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;COIJXOC5|IN88UeKh NWC4[WJnPCCm MW\k[YNz\WG|ZYOgeIhmKGOnbHyg[5Jwf3SqIEK0MlgmKGOxbXLpcoVlKHerdHigS3NMOTJ4 NITvNYozPTR5N{O0NC=>
BGC-823 M1zkd2Z2dmO2aX;uJGF{e2G7 Mn;UOeKh|ryP M2njU|czKGh? NY\jNFBn\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>? MWWyOVQ4PTd|Mx?=
MKN28 NIe0[W5HfW6ldHnvckBCe3OjeR?= M{PjbFXDqM7:TR?= NH3qfFM4OiCq M{HEZYRm[3KnYYPld{B1cGViUGLMMVMheHKxdHXpckBt\X[nbDDzbYdvcW[lYX70cJk> MUWyOVQ4PTd|Mx?=
SGC-7901 M1LXNWZ2dmO2aX;uJGF{e2G7 MmrxOeKh|ryP M13jUlczKGh? MYjk[YNz\WG|ZYOgeIhmKFCUTD2zJJBzd3SnaX6gcIV3\Wxic3nncoln[2GwdHz5 NUHmSmpHOjV2N{W3N|M>
MKN45 NGPTeodHfW6ldHnvckBCe3OjeR?= M1mwS|XDqM7:TR?= MnzXO|IhcA>? NHLieWVl\WO{ZXHz[ZMhfGinIGDSUE0{KHC{b4TlbY4hdGW4ZXygd4lodmmoY3HueIx6 M3rmOFI2PDd3N{Oz
BGC-823 M4LGNGZ2dmO2aX;uJGF{e2G7 NInpR3A2yqEQvF2= NY[wOndlPzJiaB?= MUHk[YNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7 M3Pz[FI2PDd3N{Oz
MKN28 M{PVZmZ2dmO2aX;uJGF{e2G7 NFO0bmk2yqEQvF2= MkT0O|IhcA>? NVfhW5RH\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gVHJNNTNic3nncolncWOjboTsfS=> NUjmRphLOjV2N{W3N|M>
SGC-7901 MYnGeY5kfGmxbjDBd5NigQ>? NF3lZoc2yqEQvF2= MXG3NkBp NUTzOFd[\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gVHJNNTNic3nncolncWOjboTsfS=> NGjJZZozPTR5NUezNy=>
MKN45 M1zJXWZ2dmO2aX;uJGF{e2G7 MonWOeKh|ryP NXLhNI5DPzJiaB?= M{X6bIRm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIGDSUE0{KHOrZ37p[olk[W62bIm= MkHQNlU1PzV5M{O=
HREC Ml\6SpVv[3Srb36gRZN{[Xl? MVO1M|ExyqEQvF2= NIO0VlE1QCCq MYrpcoR2[2W|IGDFSGYhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M17Nc|I2OzV{N{S3
HRPE MWjGeY5kfGmxbjDBd5NigQ>? MXe1M|ExyqEQvF2= M1nXTlQ5KGh? NUH5c5cycW6mdXPld{BRTUSIIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NVnzblZLOjV|NUK3OFc>
HREC NVf2dYl6TnWwY4Tpc44hSXO|YYm= M2\PblUwOTEEoN88US=> M3zEclQ5KGh? Ml[w[I94di2{ZXf1cIF1\XNib3[gWmVITixiSVPBUU0yKCiwb4SgdJJwfGWrbjDs[ZZmdCCrbjDIVnBGKGOnbHzzLUwhUUxvMd8yJIRwe2VvZHXw[Y5l\W62bIm= NX3WT2s6OjV|NUK3OFc>
HRPE MYnGeY5kfGmxbjDBd5NigQ>? M4nyfFUwOTEEoN88US=> MmnxOFghcA>? M3vOVoRwf25vcnXneYxifGW|IH;mJHZGT0ZuIFnMMVHPuixiYX7kJG1OWDJiZH;z[U1l\XCnbnTlcpRtgQ>? NGTqVIEzPTN3Mke0Oy=>
MSCs NWDZNGxsTnWwY4Tpc44hSXO|YYm= NETjZWIyOCEQvF2= NHfZ[GszPCCq MW\wdo9ud3SnczD0bIUh[2:vbXn0cYVvfCCxZjDNV2N{KHSxIH35c4NiemSrYXyg[Iln\mW{ZX70bYF1cW:w MXSyOVM2OTN7NR?=
HL-60 NFK0U3BHfW6ldHnvckBCe3OjeR?= MV21JO69VQ>? MkKzO|IhcA>? NY[5NIVLTE2VTx?= M3zmVJNq\26rZnnjZY51dHlidYDy[Yd2dGG2ZYOgXm5HOzh{IHX4dJJme3Orb36= MorCNlU{OTlyNEm=
MV4-11 MlPsSpVv[3Srb36gRZN{[Xl? M1fzcVUh|ryP NHvmNXY4OiCq MUXEUXNQ NY\SeZBke2mpbnnmbYNidnSueTD1dJJm\3WuYYTld{BbVkZ|OEKg[ZhxemW|c3nvci=> NUPNW4cyOjV|MUmwOFk>
A2780 NYC5OFRDTnWwY4Tpc44hSXO|YYm= MXe1JOK2VcLi NUS4cplRPyCm MX;pcoNz\WG|ZYOgSG5CKG2ndHj5cIF1cW:wIHzleoVt NYDhS2plOjV{OUm2PVQ>
CP70 Mkm3SpVv[3Srb36gRZN{[Xl? M2DqSlUhyrWPwrC= NWLucWZmPyCm NFnKSotqdmO{ZXHz[ZMhTE6DIH3leIh6dGG2aX;uJIxmfmWu NEDCPZozPTJ7OU[5OC=>
A2780 MmHESpVv[3Srb36gRZN{[Xl? NVz2c|VLPSEEtV5CpC=> NFXR[oI4KGR? MmT0e4Vic2WwczD0bIUhdGW4ZXygc4YhdWW2aInsZZRqd25? NIjC[FAzPTJ7OU[5OC=>
CP70 NH3GRnFHfW6ldHnvckBCe3OjeR?= NVTmNFJWPSEEtV5CpC=> MUi3JIQ> M1LJdZdm[WunboOgeIhmKGyndnXsJI9nKG2ndHj5cIF1cW:w MYqyOVI6QTZ7NB?=
OCM3 NWTldZVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmwMlUwOS9{IN88US=> NEjOSGE4KGR? MYXEUXNQ MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M3:ydlI2OTR4OUix
92.1 M13EVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fjTVAvPS9zL{Kg{txO MkTXO{Bl M1PC[GROW09? M13IO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M3zabFI2OTR4OUix
OCM1 MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj4dJkxNjVxMT:yJO69VQ>? MYe3JIQ> MlHJSG1UVw>? NVHBS5dycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NXjBR2hROjVzNE[5PFE>
OMM1 M{jmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4juR|AvPS9zL{Kg{txO NIL2[IY4KGR? MYLEUXNQ NHOxOZBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NWT1UmV1OjVzNE[5PFE>
Mel 285 M4DyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWwMlUwOS9{IN88US=> NEXoPIM4KGR? NH7acYJFVVOR NHPwdYFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NF\DcG8zPTF2Nkm4NS=>
Mel 290 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfHZWQxNjVxMT:yJO69VQ>? MXe3JIQ> M{DKVWROW09? MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MWKyOVE1Pjl6MR?=
OCM3 MUDGeY5kfGmxbjDBd5NigQ>? Mn22NE42NzFizszN MXu0PEBp MnHmSG1UVw>? NYfrV4lW\GWlcnXhd4V{KGOub37v[4VvcWOrdImg[I9{\S2mZYDlcoRmdnSueR?= MmniNlUyPDZ7OEG=
92.1 MXHGeY5kfGmxbjDBd5NigQ>? MoXaNE42NzFizszN MX[0PEBp M2X6emROW09? M{nTR4Rm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl? NGHiUIozPTF2Nkm4NS=>
OCM1 NYTWb2RRTnWwY4Tpc44hSXO|YYm= NF7hSW0xNjVxMTFOwG0> Mo\COFghcA>? NGjvUIJFVVOR MXTk[YNz\WG|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6 MoD6NlUyPDZ7OEG=
OMM1 NFzmZ29HfW6ldHnvckBCe3OjeR?= NXzRTnlbOC53L{Gg{txO M1;oZlQ5KGh? MV7EUXNQ MnPa[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? MU[yOVE1Pjl6MR?=
Mel 285 M2fJUmZ2dmO2aX;uJGF{e2G7 MVuwMlUwOSEQvF2= MWK0PEBp NGfhb2lFVVOR MkPJ[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? MoDONlUyPDZ7OEG=
Mel 290 MY\GeY5kfGmxbjDBd5NigQ>? M3XBS|AvPS9zIN88US=> M1jVb|Q5KGh? MmfUSG1UVw>? NGL2PZJl\WO{ZXHz[ZMh[2yxbn;n[Y5q[2m2eTDkc5NmNWSncHXu[IVvfGy7 M1zoTFI2OTR4OUix
OCM3 M364[mZ2dmO2aX;uJGF{e2G7 NF;zeVUxNjVxMTFOwG0> MX20PEBp NULoZ5JWTE2VTx?= Mn:w[IVkemWjc3XzJIlvfmG|aX;uJIRwe2ViZHXw[Y5l\W62bIpCpC=> NV;hWHc5OjVzNE[5PFE>
Mel 290 NYXsNXBETnWwY4Tpc44hSXO|YYm= NEPKfG0xNjVxMTFOwG0> MUe0PEBp MW\EUXNQ MlnH[IVkemWjc3XzJIlvfmG|aX;uJIRwe2ViZHXw[Y5l\W62bIpCpC=> M1vqNFI2OTR4OUix
OMM1 MVfGeY5kfGmxbjDBd5NigQ>? MUGwMlUwOSEQvF2= NEe1NnI1QCCq NGi5TlRFVVOR NY\idoNF\GWlcnXhd4V{KGmwdnHzbY9vKGSxc3Wg[IVx\W6mZX70cJnDqA>? NIfkVVMzPTF2Nkm4NS=>
OCM1 NIfnT4JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGDYZ3QxNjVxMTFOwG0> NXqwcGkyPSCm MnLrSG1UVw>? MWXk[YNz\WG|ZYOgdoFlcWG2aX;uMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHliaX7obYJqfGmxbh?= NHnTOGczPTF2Nkm4NS=>
92.1 M1jSSWNmdGxiVnnhZoltcXS7IFHzd4F6 MVSwMlUwOSEQvF2= M{HJOlUh\A>? M1LtTmROW09? M4jjToRm[3KnYYPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDpcohq[mm2aX;u M4\FclI2OTR4OUix
OCM1 MULGeY5kfGmxbjDBd5NigQ>? MortNE42NzFizszN NHy5SXQ1QCCq MnnHSG1UVw>? NGfZVGNk[XW|ZYOg[4xw[mGuIFTORUBpgXCxbXX0bJlt[XSrb36gZZQhVC1zIILldIVifCCub3Pp M3rjNFI2OTR4OUix
OCM3 NV7Ud5RZTnWwY4Tpc44hSXO|YYm= M2LYVFAvPS9zIN88US=> MnLGOFghcA>? M4r2bWROW09? M1;RW4NifXOnczDncI9j[WxiRF7BJIh6eG:vZYTofYxifGmxbjDheEBNNTFicnXw[YF1KGyxY3m= M3rzPFI2OTR4OUix
92.1 NInJTZFHfW6ldHnvckBCe3OjeR?= NGrPdVAxNjVxMTFOwG0> Mni0OFghcA>? NYfYS2d6TE2VTx?= NInZeXBk[XW|ZYOg[4xw[mGuIFTORUBpgXCxbXX0bJlt[XSrb36gZZQhVC1zIILldIVifCCub3Pp MUGyOVE1Pjl6MR?=
IMR32 NHvGTGZHfW6ldHnvckBCe3OjeR?= MoTDN{DPxE1? NHrjNIo4OiCq MX;EUXNQ MXvpcoR2[2W|wrDwNVkuUU6NNHVCpIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm= NYLHOYw3OjVzMES4OVA>
IMR5-75 NGG1cGVHfW6ldHnvckBCe3OjeR?= Mo\sN{DPxE1? NIDzWZo4OiCq NVTq[oxlTE2VTx?= NVnWTlh6cW6mdXPld:KheDF7LVnOT|RlyqCneIDy[ZN{cW:wwrDzbYdvcW[rY3HueIx6 NHzUU2ozPTFyNEi1NC=>
Be(2)-C MY\GeY5kfGmxbjDBd5NigQ>? NV:yO|gyOyEQvF2= MkTiO|IhcA>? NEHrNIxFVVOR NXXPb5dPcW6mdXPld:KheDF7LVnOT|RlyqCneIDy[ZN{cW:wwrDzbYdvcW[rY3HueIx6 NF\YbWkzPTFyNEi1NC=>
Bxpc-3 NF;rWY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni0OU8yOCEQvF2= M4DobFI1NzR6L{eyJIg> MYLpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBDgHClLUOgZ4VtdHNiaX6geIlu\S1iYX7kJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5menN? NITpfWMzPTB4MUezNS=>
Bxpc-3 NYr2eoVMSXCxcITvd4l{KEG|c3H5 MVG1M|ExKM7:TR?= M3:2TlI1NzR6L{eyJIg> MWPpcoR2[2W|IHHwc5B1d3OrczDpckB1cW2nLTDhcoQh[2:wY3XycpRz[XSrb36gcYFvdmW{cx?= MnjpNlUxPjF5M{G=
Bxpc-3 MWfGeY5kfGmxbjDBd5NigQ>? NX7l[mdoPS9zMDFOwG0> MXqyOE81QC95MjDo M3;ZfIRm[3KnYYPld{DPui2lYYTlcolvKGW6cILld5Nqd25iYX\0[ZIhOjRiaB?= MV6yOVA3OTd|MR?=
Bxpc-3 NF;wXllHfW6ldHnvckBCe3OjeR?= NEP6VZA2NzFyIN88US=> M1rRUlI1NzR6L{eyJIg> NXPScY9H\GWlcnXhd4V{KGO7Y3zpcmQyKGW6cILld5Nqd25iYYSgeIhmKGOxbnPldo51emG2aX;uJI9nKDFyIN88US=> M4OzO|I2ODZzN{Ox
Bxpc-3 M1XzVWZ2dmO2aX;uJGF{e2G7 NHHNUGI2NzFyIN88US=> Mn;VNlQwPDhxN{KgbC=> NIHtSoRld3ewLYLl[5Vt[XSnUzDjMY16[yCvUl7BJIV5eHKnc4Ppc44hcW5idHnt[U0h[W6mIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldpM> NGTsSGIzPTB4MUezNS=>
HL-60 NUTCZ2M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTYfHYyNjBizszN M1v6WlQ5KGh? NETPRY9{cWewaX\pZ4FvfGy7IHnubIljcXS|IFjMMVYxKGOnbHyg[5Jwf3SqwrC= MViyOVA2OTFzOR?=
HL-60 MnTNSpVv[3Srb36gRZN{[Xl? MlHFNU4xKM7:TR?= M4LlWlQ5KGh? M4jwU4lv[3KnYYPld{BxOjGZQV[xM2NKWDIEoHHu[EBk[XOyYYPlMVMh\XiycnXzd4lwdsLi NXT1[olnOjVyNUGxNVk>
HL-60 MYDGeY5kfGmxbjDBd5NigQ>? NVTufXVzOS5yIN88US=> MoTNOFghcA>? M2TQWYRm[3KnYYPld{BD[2xveFyg[ZhxemW|c3nvcuKhe2mpbnnmbYNidnSueR?= M1\1RVI2ODVzMUG5
HuTu-80  MlHXSpVv[3Srb36gRZN{[Xl? NVn3XIlDOS93L{GwJO69VQ>? MoK2OFgwPzJiaB?= MmTabY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIh2dWGwIF7QR|FNOSCvUl7BJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXGyOFkxPDB4Mh?=
Caco2  MVLGeY5kfGmxbjDBd5NigQ>? MnTINVAh|ryP Mlf2OFghcA>? NWC5SoxWcW6lcnXhd4V{KE6SQ{HMNUBmgHC{ZYPzbY9v NXHuTVhHOjR7MESwOlI>
HepG2  M{DvS2Z2dmO2aX;uJGF{e2G7 NYD5TpkxOC1{NTFOwG0> M1Hvb|I1KGh? NYf2[ZBY\GWlcnXhd4V{KHO3YoTpcIl{cW5xa3X4bY4hfHmyZTC5JEhRS1ONOTmgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgQ>? NVfmOHlCOjR6NUW2OFY>
HepG2  MUDGeY5kfGmxbjDBd5NigQ>? M3z3eFAuOjVizszN Mnz3NlQhcA>? MonYbY5kemWjc3XzJIxwfyCmZX7zbZR6KGyrcH;wdo91\WmwIILlZ4VxfG:{IDjMSGxTMSCpZX7lJIV5eHKnc4Ppc47DqA>? MYSyOFg2PTZ2Nh?=
HepG2  MX3GeY5kfGmxbjDBd5NigQ>? Mmj3NVAh|ryvwrC= NIOxOXoxNTJ2IHi= MmXi[IVkemWjc3XzxsBRS1ONOdMgZY5lyqCKTVfDVuKh\XiycnXzd4lwdiCjbnSgbY5kemWjc3XzJGxFVFJiZYjwdoV{e2mxbjDh[pRmeiB4IHi= M1nOZlI1QDV3NkS2
HepG2  NGjQSI1HfW6ldHnvckBCe3OjeR?= NWiwWVdxOTBizszt MViyOEBp MUXwdo9ud3SnczDjfZRwe2:uaXOgcoV2fHKjbDDsbZBq\CCjY3P1cZVt[XSrb36gbY5l\XCnbnTlcpRtgSCxZjDlfI9o\W6xdYOgcIlxd3C{b4TlbY5{ M4j6[lI1QDV3NkS2
HepG2  NIn2eIpHfW6ldHnvckBCe3OjeR?= MYKxNEDPxG1? NWDsfHpLOjRiaB?= NGj3e3BxemW4ZX70d{BUWkWEUDDwdo9k\XO|aX7n MorqNlQ5PTV4NE[=
HC45  MkP1SpVv[3Srb36gRZN{[Xl? M1XmNlXDvU4EoB?= M4XzUlQh\A>? NHjNNWlz\WS3Y3XzJJRp\SCvZYTofYxifGmxbjDs[ZZmdHNib3[gW2lHOSxiUEG2MEBEYEOOMUSsJG5MYDMkgKOzMEBETEhzLDDMRW1COSxiYX7kJGNVVk6EMR?= NI\IVnEzPDd4MkiwPS=>
CNDT2  NIHZT|VHfW6ldHnvckBCe3OjeR?= MUO1xtVOyqB? NHfSNIE1KGR? NGnxWZJz\WS3Y3XzJJRp\SCvZYTofYxifGmxbjDs[ZZmdHNib3[gW2lHOSxiUEG2MEBEYEOOMUSsJG5MYDMkgKOzMEBETEhzLDDMRW1COSxiYX7kJGNVVk6EMR?= M2j5V|I1PzZ{OEC5
CNDT2  NVzScplsTnWwY4Tpc44hSXO|YYm= Mnr5OeK2VcLi NUPMV2NCPCCm M4TKfolv[3KnYYPld{Bo\W6nIHX4dJJme3Orb36gc4bDqFeLRkGsJHAyPixiQ1TINUzDqEyDTVGxMOKh[W6mwrDDWG5PSjF? NUW1Z|JoOjR5NkK4NFk>
T-cells NVy5N45ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LpbFUwOjBizszN NHfqeXMxNTR6IHi= M2jEe4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NIPi[HYzPDd3N{K4Ny=>
CD3+ T-cells Mmr6SpVv[3Srb36gRZN{[Xl? NXXiTYhvPS9{MDFOwG0> MnP2OFghcA>? M4HFPZVxemWpdXzheIV{KHBzNTDlfJBz\XO|aX;u M37tPVI1PzV5Mkiz
CD4+ T-cells M2n2NGZ2dmO2aX;uJGF{e2G7 MX21M|IxKM7:TR?= NXm1eVRWPDhiaB?= NGKzSlF2eHKnZ4XsZZRmeyCyMUWg[ZhxemW|c3nvci=> NUTrZWtmOjR5NUeyPFM>
CD8+ T-cells MUnGeY5kfGmxbjDBd5NigQ>? NWHBd41GPS9{MDFOwG0> NIe0NWg1QCCq MY\1dJJm\3WuYYTld{BxOTViZYjwdoV{e2mxbh?= MXOyOFc2PzJ6Mx?=
CD3+ T-cells NH;yR5VHfW6ldHnvckBCe3OjeR?= MmTLOU8zOCEQvF2= NWDSdHpNPDhiaB?= M2PBcZVxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKE[RWGCz MXGyOFc2PzJ6Mx?=
CD4+ T-cells M2fhNGZ2dmO2aX;uJGF{e2G7 MUO1M|IxKM7:TR?= NWX3NlJsPDhiaB?= NGPhXZl2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCIT2jQNy=> NFK0bFYzPDd3N{K4Ny=>
CD4+ T-cells NGT4XGVHfW6ldHnvckBCe3OjeR?= NEjxSYc2NzJyIN88US=> MoDuOFghcA>? NYKzVldzemWmdXPld{BVSkWWMdMgcXJPSSCneIDy[ZN{cW:w MmO0NlQ4PTd{OEO=
CD4+ T-cells NGDXPIZHfW6ldHnvckBCe3OjeR?= M4DZZVUwOjBizszN MmjKOFghcA>? NFS5ZWV2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\sLiUl;S{tN1yqB? MnTBNlQ4PTd{OEO=
CD4+ T-cells M4rmfGZ2dmO2aX;uJGF{e2G7 MkS3OU8zOCEQvF2= Mn;ROFghcA>? NFm1coFqdmirYnn0d{Bu\W2xcomgWE1k\Wyucx?= M{\pUlI1PzV5Mkiz
CD8+ T-cells M3Gy[WZ2dmO2aX;uJGF{e2G7 NELqcpQ2NzJyIN88US=> M{[x[|Q5KGh? NYD5eoNGcW6qaXLpeJMhdWWvb4L5JHQu[2WubIO= MoD4NlQ4PTd{OEO=
CD3+ T-cells MUXGeY5kfGmxbjDBd5NigQ>? NEjsfFA2KM7:TR?= NYXqOVlbPDhiaB?= MXzy[YR2[2W|IHzvcocufGW{bTDt[Y1wenliY3XscEBxcGWwb4T5dIU> M17jelI1PzV5Mkiz
U937 MYXBdI9xfG:|aYOgRZN{[Xl? MmnuNVAh|ryP NIXCcWk4OiCq NV[3OJQ{cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= NXP4[HRtOjR4OEC4OlU>
HL-60 NGn6WYRCeG:ydH;zbZMhSXO|YYm= M4K0fVExKM7:TR?= NFGzTZM4OiCq MVnpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 MX[yOFY5ODh4NR?=
MCF7 NIfhN4xHfW6ldHnvckBCe3OjeR?= NYTOSpJbPSEQvF2= NXHSNXZxPDhiaNMg Ml3X[Il{eGyjeYOgd4Vt\WO2aY\lJJRwgGmlaYT5JJRwf2G{ZDDzeZNx\W6mZXSgUWNHNTdiY3XscJM> M{[xVFI1PjN|M{Ww
MCF7 NIL3c4tHfW6ldHnvckBCe3OjeR?= M4\IVFExKM7:TR?= MoD5NlQhcMLi M2nTe4lv\HWlZYOgeIhmKGOuZXH2ZYdmKG:oIHPhd5Bie2ViNzDhcoQhWEGUUNMg NY\FcWNVOjR4M{OzOVA>
MCF7 MUjGeY5kfGmxbjDBd5NigQ>? M{XENFDjiJNyLkWg{txOyqB? M4LSd|ch\A>? MmTHbY5pcWKrdIOgeIhmKGe{b4f0bEBOS0ZvNzD0eY1wenOyaHXy[ZMhcW5ic4XzdIVve2mxbjDjeYx1fXKnc9Mg MknxNlQ3OzN|NUC=
MCF7 NVHKNW1xTnWwY4Tpc44hSXO|YYm= NWXRSJl6OC53IN88UeKh M2DZcFE1KGR? NXLjV4VkemWmdXPld{B1cGVic3n6[UBw\iCPQ1[tO{Bkd2yxbnnld{BmdWKnZHTl[EBqdiC|b3\0JIFo[XJ? MmjFNlQ3OzN|NUC=
MCF7 M4jI[WZ2dmO2aX;uJGF{e2G7 MUKwMlA26oDVMkCg{txO MlzkNUBl MUjy[YR2[2W|IITo[UBkdG:wYXygd5Vzfmm4YXygc4YhVUOILUegZ4VtdHNiaX6gcY9vd2yjeXXyJIN2dHS3cnXz NYPoNHM6OjR4M{OzOVA>
T47D  MYjGeY5kfGmxbjDBd5NigQ>? NFfEbVMxNjVizszN NGLTdpE1KGR? M3jxNolvcGmkaYTzJJR2dW:{c4Do[ZJmKG[xcn3heIlwdg>? MVyyOFY{OzN3MB?=
MCF7 M{XaTmZ2dmO2aX;uJGF{e2G7 NFvVZlcxNjYkgKOxNEDPxE1? M4T5cFQ5KGkEoB?= MUfpcohq[mm2czD0bIUh\2GyIHPsc5N2emViaX6geIhmKHexdX7kJIhm[WyrbnegZZN{[Xl? M3;wVVI1PjN|M{Ww
MCF7 NW\LW2htTnWwY4Tpc44hSXO|YYm= M3XVN|AwOTBizszN NHnKW4UzPCCq MmrVbY5pcWKrdIOgeIhmKGGldHn2bZR6KG:oIF3NVFk> NHPlVZUzPDZ|M{O1NC=>
MDA-MB-231  M3zQWGZ2dmO2aX;uJGF{e2G7 NETWcJExNjYkgKOxNEDPxE1? NXu3OVlCOzZiaB?= MXfpcohq[mm2czD0bIUhdWmpcnH0bY9v MnLtNlQ3OzN|NUC=

... Click to View More Cell Line Experimental Data

In vivo Azacitidine inhibits polynucleotide synthesis in leukemic BDF1 mice. [3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. [4]

Protocol

Cell Research:[3]
+ Expand
  • Cell lines: Leukemia L1210 cell
  • Concentrations: 0.15 μg/mL
  • Incubation Time: 3 days
  • Method: 5 mL of L1210 cells (5 × 103 cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: BDF1 mice bearing lymphoid leukemia L1210
  • Formulation: Dissolved in 0.85% NaC1 solution immediately prior to use
  • Dosages: 3 mg/kg
  • Administration: Daily i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 48 mg/mL warmed (196.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO+30% PEG 300+ddH2O
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.2
Formula

C8H12N4O5

CAS No. 320-67-2
Storage powder
Synonyms NSC 102816

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02995655 Not yet recruiting Myelodysplastic Syndromes|Acute Myeloid Leukemia|AML|MDS Washington University School of Medicine|Cantex Pharmaceuticals February 28, 2017 Phase 1
NCT02750254 Recruiting Acute Myeloid Leukemia|Myelodysplastic Syndrome|Acute Lymphocytic Leukemia Washington University School of Medicine June 27, 2016 Phase 1|Phase 2
NCT02966782 Not yet recruiting Myelodysplastic Syndromes (MDS) AbbVie|Genentech, Inc. March 2017 Phase 1
NCT02959437 Not yet recruiting Advanced Solid Tumors Incyte Corporation February 2017 Phase 1|Phase 2
NCT02942758 Not yet recruiting Acute Myeloid Leukemia University Hospital Regensburg|Anticancer Fund, Belgium|Celgene February 2017 Phase 2
NCT03019003 Not yet recruiting Head and Neck Cancer Massachusetts General Hospital|AstraZeneca February 2017 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?

  • Answer:

    S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

DNA Methyltransferase Signaling Pathway Map

Tags: buy Azacitidine | Azacitidine supplier | purchase Azacitidine | Azacitidine cost | Azacitidine manufacturer | order Azacitidine | Azacitidine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID